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ABSTRACT 
Magnetic mesoporous silica microparticles were loaded with safranin O (S1) and with 
hydrocortisone (S2) and the outer surface functionalized with a bulky azo derivative 
bearing urea moieties. Aqueous suspensions of both solids at pH 7.4 showed negligible 
payload release whereas a marked delivery was observed in the presence of sodium 
dithionite due to the rupture of the azo bonds. Besides, a moderate cargo release was 
observed at acidic pH due to the hydrolysis of the urea bonds that linked the azo 
derivative onto the external surface of the inorganic scaffolds. In vitro digestion models 
showed that S1 and S2 microparticles could be used for the controlled release of 
payload in the reducing colon environment (in which azoreductase enzymes are 
present). On the other hand, in vivo pharmacokinetic studies in rats showed that 
safranine O release from S1 microparticles was concentrated in colon. The performance 
of S2 microparticles for the treatment of colitis in rats (induced by oral administration 
of a 2,4,6-trinitrobenzenesulfonic acid solution) was tested. The controlled release of 
hydrocortisone from S2 in the colon of injured rats induced marked reduction in 
colon/body weight ratio and in clinical activity score. Also, histological studies showed 
a marked decrease in inflammation followed by intensive regeneration and almost 
normal mucosal structure of the individuals treated with S2. Besides, the use of a 
magnetic belt increased the therapeutic performances of S2 due to an enhanced 
retention time of the particles in the colon. 
 
KEYWORDS 
Colon drug delivery systems; colon targeting; inflammatory bowel disease; mesoporous 
silica microparticles; gated materials; smart drug delivery  
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INTRODUCTION 
Inflammatory bowel diseases (IBD) are autoimmune, inflammatory, chronic 
malignances affecting the gastrointestinal tract tissue, mainly the colon, which is a 
difficult area to treat.[1–5] Although the etiology of IBD is still unknown, some authors 
have reported that a mix of genetic, environmental factors and some dietetic habits may 
favor the establishment and proliferation of these diseases. There are two main diseases 
classified as IBD, ulcerative colitis and Crohn’s disease.[3,4] Ulcerative colitis affects 
exclusively the colon mucosa (first layer from the luminal face) and the injuries caused 
present a continuous distribution. Meanwhile, Crohn’s disease affects all layers 
(transmural) along the gastrointestinal tract from the mouth until the last portion of the 
rectus, with injuries distributed in patches (injured areas surrounded by healthy areas). 
IBD have a big impact in our society since its incidence and prevalence is continuously 
increasing in both, developed and developing countries.[6–8] Most common treatments 
for IBD are based on non-specific anti-inflammatory drugs focused on the relief of 
ulcers and fissures or the damaged tissue.[9–11] These treatments present some 
disadvantages such as the presence of adverse effects or the low drug efficacy due to the 
drug systemic absorption in the first segment of the small intestine. Taking this into 
account, the development of new drug carriers for oral IBD treatment to decrease 
adverse effects and enhance drug efficacy is a research field with marked interest. With 
this aim, smart formulations for targeting colon such as pH-responsive biodegradable 
polymers, time-dependent formulations, pressure responsive systems, osmotic 
controlled materials, bio-adhesive systems, enzyme triggered prodrugs or drugs coated 
with enzyme-sensitive polymers have been recently developed.[12–14] In fact, enzymes 
produced by colon microbiota (such as azoreductase, ß-galactosidase, ß-xylosidase, 
nitroreductase, glycosidase deaminase) are ideal candidates to be used as external 
triggers in the preparation of smart controlled release carriers.[15–17]  
From another point of view, the blending of material and supramolecular chemistry 
concepts has resulted in recent years in the development of innovative examples of 
smart hybrid organic-inorganic micro or nanodevices able to perform programmed 
functions.[18] In the vast realm of these smart nanodevices those equipped with 
“molecular gates” are highly appealing because allow mass transport upon application 
of an external trigger.[19] These “gated materials” are generally formed by two 
components: (i) an inorganic porous support, which is able to entrap selected chemicals, 
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and (ii) supramolecular or (bio)molecular entities, grafted onto the outer surface, which 
control cargo release upon application of an external stimuli.[20] Dealing with the 
inorganic supports mesoporous silica has been extensively used for the preparation of 
these “gated materials”. This is due to its positive features, such as relatively well-
known functionalization chemistry, inertness, chemical stability, presence of controlled 
pore diameter within the nanometric range (ca. 2–3 nm), and large specific surfaces (up 
to 1200 m
2
 g
−1
) and specific volumes.[21] Besides, mesoporous silica can be prepared 
in the form of nano or microparticles. A high number of gated materials containing 
different payloads and able to selectively deliver their cargo upon application of 
chemical, physical or biochemical stimuli have been reported.[19] In fact, the 
incorporation of gate-like ensembles on the external surface of mesoporous silica 
particles is a suitable and promising approach to design devices with applications in 
controlled release protocols in biological, pharmaceutical and medical fields.[22,23] 
“Gated materials” have mainly been used for drug delivery applications, and the 
preparation of carriers able to release certain drugs on the site of action at-will, 
minimizing secondary effects is a benchmark in the treatment of different diseases. 
Gated mesoporous supports have also been applied recently in sensing/recognition 
protocols and in chemical communication networks.[24–26] However, it is also 
apparent from the literature that, gated hybrid organic-inorganic materials have not been 
used for the development of smart formulations for IBD treatment. 
Bearing in mind our interest in the development of silica-based gated materials for 
controlled release applications,[27–34] we report herein the preparation of micro-sized 
silica mesoporous solids containing magnetic nanoparticles (S1 and S2) as potential 
systems designed to release an entrapped cargo in colon. The magnetic character of the 
solids may be useful to enhance the retention time of the particles in the part of interest 
of the intestinal tract (ileum or colon). Particles S1 and S2, contained a dye (safranin O) 
and a model drug (hydrocortisone) in the pores were capped with a bulky azo derivative 
by means of a urea bond. We demonstrated that the presence of bulky azoderivatives 
onto the external surface of S1 and S2 inhibited cargo delivery yet both solids were able 
to deliver their cargo in the presence of a reducing agent (sodium dithionite) and to 
some extent at acidic pH (due to partial hydrolysis of urea bonds that linked the azo 
derivative onto the inorganic support). Studies on cargo delivery from S1 in a simulated 
digestive process in mouth, stomach, small intestine and colon is also reported. Finally, 
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in vivo studies with S1 were also performed to check the pharmacokinetics of this new 
nanodevice and S2 was used to prove its efficacy in an in vivo ulcerative colitis model. 
 
MATERIALS AND METHODS 
Chemicals 
The chemicals tetraethylorthosilicate (TEOS), n-cetyltrimethylammonium bromide 
(CTABr), sodium hydroxide, triethanolamine (TEAH3), (3-
Isocyanatopropyl)triethoxysilane, iron(III) chloride hexahydrate, iron(II) chloride 
tetrahydrate, oleic acid, safranin O, triethylamine, Congo red, sodium dithionite, 
hydrocortisone, and 2,4,6-trinitrobenzenesulfonic acid solution (TNBS), were provided 
by Sigma-Aldrich. Disodium hydrogen phosphate, sodium dihydrogen phosphate, 
potassium dihydrogen phosphate, sodium chloride, potassium chloride, sodium acetate 
anhydrous and all the analytical-grade solvents were purchased from Scharlab. 
Isoflurane, pentobarbital (dolethal
®
) was acquired from the animal facilities. All 
products were used as received. 
Synthesis of oleic acid-coated magnetic nanoparticles (MNPs) 
MNPs were prepared using a modified co-precipitation method. In a typical procedure, 
FeCl3·6H2O (24.0 g, 0.089 mol) and FeCl2·4H2O (9.8 g, 0.049 mol) were dissolved in 
deionized water (100 mL) under nitrogen atmosphere with vigorous stirring at 80°C. 
Then ammonium hydroxide (50 mL) was added quickly into the solution. The color of 
the solution immediately turned black and then oleic acid (3.8 g, 0.013 mol) was added 
after 30 min. The reaction was kept at 80°C for 1.5 h. The final oleic acid-coated MNPs 
were washed with deionized water until neutral pH. Afterward, the MNPs were 
transferred into a chloroform solution (30 mg MNPs/mL CHCl3). 
 
Synthesis of mesoporous silica microparticles containing MNPs (S0) 
A chloroform suspension of MNPs (6 mL, 30 mg MNPs/mL CHCl3) was mixed with an 
aqueous solution of CTABr (8 mL, 10 mg/mL) and the resulting mixture was 
homogenized (using a sonicator) and heated. Finally, the suspension was sonicated 
again and passed through nylon filters (0.45 µM) to ensure MNPs homogeneity. 
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Magnetic micro-sized MCM-41 particles were synthesized following the so-called 
‘‘atrane route”. For this purpose, a solution of TEAH3 (25.79 g, 0.173 mol) and NaOH 
(2 mL of a 6 M solution) was heated to 120
o
C and then cooled down to 70
o
C, at this 
moment TEOS (11 mL, 0.045 mol) was added and the crude reaction was heated up to 
120
o
C. The crude reaction was left cooling down again and CTABr (4.68 g, 0.013 mol) 
was added at 118°C. Next, water containing MNPs (74 mL of distilled water + 6 mL of 
the MNPs CTABr-water suspension) was slowly added with vigorous stirring at 70°C. 
Besides, NaOH (10 mL of a 0.1 M solution) was added to obtain a pH ≈ 10.9. After a 
few minutes, a brownish suspension was formed. This mixture was aged in an autoclave 
at 100
o
C for 24 h. The resulting powder was collected by filtration and washed with 
water. Finally, the solid was dried at 70°C. To prepare the final solid (S0), the as-
synthesized microparticles were calcined at 550°C using oxidant atmosphere for 5 h in 
order to remove the template. 
 
Synthesis of 1 
Congo red (1a in Scheme 2, 8.1 g, 10 mmol) was dissolved in anhydrous N,N-
dimethylformamide (120 mL) and then (3-Isocyanatopropyl)triethoxysilane (1b in 
Scheme 2, 5.21 mL, 20 mmol) and trimethylamine (2 droplets) were added under argon 
atmosphere. The crude reaction was allowed to react for 36 h at 100ºC. The solvent was 
eliminated in a rotary evaporator and the final product 1 isolated as dark red oil (11.4 gr, 
10 mmol, 96% yield). 
1
H NMR (400 MHz, DMSO-D6): =8.79 (d, 2H), 8.47 (d, 2H), 
8.36 (s, 2H), 8.12 (d, 4H), 7.96 (d, 4H), 7.78 (br s, 2H), 7.61 (t, 2H), 7.51 (t, 2H), 5.83 
(br s, 2H), 3.73 (q, 12H), 2.93 (m, 4H), 1.40 (m, 4H), 1.14 (t, 18H), 0.51 (t, 4H) ppm; 
13
C: = 158.3, 152.4, 145.9, 140.1, 132.4, 131.9, 129.1, 128.3, 127.5, 125.0, 124.4, 
123.9, 122.9, 118.3, 57.8, 56.2, 42.2, 23.8, 18.5, 18.2, 7.4 ppm. HRMS-EI m/z: calcd for 
C52H64N8O14S2Si2 572.1766; found: 544.3443 (M─2 EtOH from the trialkoxysilane 
group). 
 
Synthesis of S1 
MCM-41 magnetic mesoporous silica microparticles (S0, 160 mg) were suspended in 
an acetonitrile solution (10 mL) of safranin O (45 mg, 0.8 mmol/g S0) under argon 
atmosphere. The obtained suspension was then stirred at room temperature overnight. 
Afterward, 1 (1.89 g, 10 mmol/g S0) was dissolved in anhydrous N,N-
dimethylformamide (25 mL) and was added to the microparticle/dye suspension. The 
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mixture was stirred at room temperature for 6 h in an argon atmosphere. S1 was isolated 
as a dark red solid, after several DMF and H2O washes, by centrifugation and was dried 
at 40 ºC for >24 h.  
 
Synthesis of S2 
MCM-41 magnetic mesoporous silica microparticles (S0, 330 mg) were impregnated 
with 3.34 mL of a hydrocortisone ethanolic solution (15 mg/mL) in a 2 cycles 
impregnation procedure. At this respect, 330 mg of S0 were sunk in 1.67 mL of 
hydrocortisone ethanolic solution. Then the particles were left drying at 40ºC for 30 min 
(this step was performed two-times). Afterward, 1 (3.9 g, 10 mmol/g S0) was dissolved 
in a DMF-water 95:5 v/v solution (50 mL) and was added to the loaded microparticles. 
The mixture was stirred at room temperature for 6 h. S2 was isolated as a red solid, after 
several ethanol and H2O washes, by centrifugation and was dried at 60 ºC overnight. 
Characterization 
Transmission electron microscopy (TEM), scanning transmission electron microscopy 
(STEM), powder X-ray diffraction (PXRD), thermogravimetric analysis (TGA), N2 
adsorption-desorption, nuclear magnetic resonance (NMR), Fourier transform infrared 
spectroscopy (FT-IR) and high-performance liquid chromatography (HPLC) techniques 
were employed to characterize the synthesized materials. TEM and STEM images were 
acquired using a JEOL JEM-1010 and a JEOL JEM 2100F microscopes, respectively. 
PXRD measurements were performed on a Bruker D8 Advance diffractometer using 
CuK radiation. TGA were carried out on a TGA/SDTA 851e Mettler Toledo balance, 
using an oxidant atmosphere (air, 80 mL/ min) with a heating program consisting on a 
heating ramp of 10°C per minute from 393 to 1273 K and an isothermal heating step at 
this temperature for 30 min. N2 adsorption-desorption isotherms were recorded with a 
Micromeritics ASAP 2010 automated sorption analyzer. The samples were degassed at 
120°C under vacuum overnight. The specific surface areas were calculated from the 
adsorption data in the low pressure range using the Brunauer–Emmett–Teller (BET) 
model. Pore size was determined following the Barrett-Joyner-Halenda (BJH) method. 
1
H NMR spectra were recorded using a Bruker AV400 spectrometer. Infrared spectra 
were recorded using a Bruker Tensor 27 equipment. The HPLC instrument consisted of 
a Hitachi LaChrom Elite liquid chromatograph (Hitachi Ltd., Tokyo, Japan) equipped 
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with an auto-sampler (module L-2200), UV detector (model L-2400) and a Kromaphase 
100 C18 (150 mm × 4.6 mm i.d., 5-μm particle size analytical column) (Scharlab, 
Barcelona, Spain) was used for separations. 
Release studies 
Controlled release studies from S1 and S2 were performed at different pH values (i.e. 
2.0, 4.5 and 7.4) and in the presence of a reductive environment (sodium dithionite, 
which is known to reduce azo linkages). In a typical experiment, 2 mg of the 
corresponding solid were suspended in water at the selected pH (2 mL) and aliquots 
were extracted at given times (0, 5 min, 20 min, 40 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h) 
and centrifuged to remove the solid before analyzing. Controlled release experiments 
were done in triplicate in order to obtain standard deviation values. 
Controlled release from S1 and S2 microparticles was also tested under in vitro 
digestion conditions using simulated solutions for saliva, gastric juice, duodenal juice 
and bile. In vitro digestion experiments were carried out with S1 and S2 (2 mg) at 37ºC 
(temperature of the human body) and stirring at 100 rpm (in order to ensure the correct 
suspension of the microparticles). Digestions started by adding simulated saliva fluid 
(320 µL) and incubating for 5 min. Then, simulated gastric juice (630 µL) was added, 
and the mixture was stirred for 2 h. Later, simulated duodenal juice (630 µL), bile (320 
µL) and a bicarbonate solution (1 M, 100 µL) were added simultaneously and the 
mixture was stirred for another 2 h. Finally, colon fluid was simulated by adding 
sodium dithionite (2 mg/mL). Aliquots were taken at given times from the beginning of 
the assay (0, 5, 20, 35, 65, 95, 125, 155, 185, 215, 245, 260 275, 305, 365, 425, 485, 
1320 and 1685 min), centrifuged and then analyzed.  
To quantify the amount of cargo released S1 supernatants were loaded into 96 well plate 
to measure safranin O fluorescence at 571 nm (excitation at 520 nm). For S2 samples, 
supernatants were analyzed by HPLC to measure the hydrocortisone released. 
Calibration curves were used to assess the amounts of safranin O and hydrocortisone 
released from solids S1 and S2 in the different environments tested. 
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Hydrocortisone quantification 
Hydrocortisone was determined by reversed-phase HPLC according to the method 
described by Navarro and co-workers with several modifications.[35] The HPLC 
instrument consisted of a Hitachi LaChrom Elite liquid chromatograph (Hitachi Ltd., 
Tokyo, Japan) equipped with an auto-sampler (module L-2200) and UV detector (model 
L-2400). A Kromaphase 100 C18 (150 mm × 4.6 mm i.d., 5-μm particle size analytical 
column) (Scharlab, Barcelona, Spain) was used for separations. The mobile phase 
consisted of (A) water and (B) acetonitrile. The program was isocratic for 15 min with 
70% A and 30% B. The wavelength of the UV detector was set at 245 nm. 
Hydrocortisone was quantified according to the external standard method (since no 
matrix effect was observed) using a calibration curve of the peak area against the 
compound concentration. The applicability of this method was evaluated by performing 
a recovery study. For this purpose, digestion fluids were fortified with hydrocortisone at 
five different concentration levels. In all cases, recovery values, which were estimated 
from measured versus added amounts of hydrocortisone, were close to 100%. Thus, the 
results obtained demonstrated the applicability of the proposed methodology for the 
accurate determination of hydrocortisone in the different fluid samples. 
In vivo pharmacokinetic studies 
Male Wistar rats were used in accordance with 2010/63/EU directive of 22 September 
2010 regarding the protection of animals used for scientific experimentation. The Ethics 
Committee for Animal Experimentation of the University approved the experimental 
protocols (Spain, code A1330354541263). Male Wistar rats weighing 300 ± 30 g were 
anesthetized as described in in situ perfusion to allow cannula implantation 24 h before 
the experiment. A previously described jugular vein permanent cannulation method was 
used.[36]
 
The implanted cannula allows blood sampling. The animals were randomly 
assigned (n = 10 to 12) to the following groups: Group 1: A volume of 1 mL of safranin 
O solution (150 µg/mL saline) was given orally. Group 2: A volume of 1.75 mL of a 
suspension containing 60 mg of S1 (that should release ca. 150 µg of safranin O) was 
given orally. Group 3: A volume of 1.75 mL of a suspension containing 60 mg of S1 
(that should release ca. 150 µg of safranin O) was given orally. In addition, the subjects 
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in this group wore a magnetic belt in the lower part in the waist to increase the retention 
time of the microparticles in the last segment of the bowel. 
Blood samples (0.6–0.7 mL) were withdrawn with heparinized syringes, and replaced 
by heparinized saline (10 IU/mL) at established sampling times (t =15’, 30’, 45’, 1 h, 2 
h, 3 h, 4 h and 5 h). Plasma was immediately separated by centrifugation (10,000 rpm 
for 10 min) and then frozen at -20°C until analysis. At the end of the 5 h the subjects 
were sacrificed and the cecum, colon and feces were collected and processed to analyze 
the presence of safranin O. Cecum, colon and feces were separated, suspended into 
buffer solution (phosphate, pH 6.8), and then centrifuged. Samples were taken and 
analyzed by HPLC (Waters Alliance
®
 e2695, Milford, MA, USA) with fluorescence 
detector using 520 and 585 nm as excitation and emission wavelengths (Waters 2486, 
Milford, MA, USA). As mobile phase acetonitrile:water 30:70 v/v with 1% of 
trifuoroacetic acid was used. A Novapack C18 (WATERS

) cartridge-type column (5 
µm, 4 mm x 200 mm) was used. Temperature was set at 25 °C, 50 µl of injection 
volume were used and a flow of 1 mL/min was fixed. The method was previously 
validated with adequate linearity, precision and accuracy (R > 0.99 and coefficient of 
variation < 5%). 
In vivo efficacy studies. Induction of colonic inflammation 
The studies reported here adhere to the Principles of Laboratory Animal Care and were 
approved by the institutional ethics committee of the University of Valencia (Spain) 
according to RD 1201/2005. These studies were carried out on male Wistar rats aged 8–
12 weeks and weighing 275–325 g. Animals were housed in an air-conditioned room at 
22 ± 3ºC, 55 ± 5% humidity, 12 h light/dark cycles and allowed free access to water and 
laboratory chow for the duration of the studies. To induce the model of chronic 
inflammation in the rat colon, the method described by Morris and co-workers was 
followed with several slight modifications.[37] Briefly, rats were arbitrarily separated 
into treatment groups, with free access to water and then anaesthetized with isoflurane. 
A graduated rubber canula was inserted rectally into the colon in such a way that the tip 
was 8 cm proximal to the anus. Then, 0.6 mL of a solution of TNBS (78 mg/kg body 
weight) dissolved in 50% ethanol (v/v) was instilled into the lumen of the colon through 
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the rubber probe (total volume 0.6 mL solution). The induction and development of 
inflammation was monitored every day during the 10 days that lasted the assays. 
Treatment studies design 
Rats were divided into 5 groups: Group 1 (positive control group, 3 rats) was 
administered with saline solution (1.5 mL). Group 2 (8 rats) received a suspension of S0 
microparticles (60 mg in 1.5 mL of saline). Group 3 (8 rats) received a hydrocortisone 
solution (1.5 mg in 1.5 mL of saline). Group 4 (8 rats) received a suspension of S2 
microparticles (60 mg in 1.5 mL of saline). Group 5 (4 rats) received a suspension of S2 
(60 mg in 1.5 mL of saline) and a magnetic belt was attached to the waist of each rat.  
The dose of hydrocortisone that received groups three to five, 5.58 mg/kg/day, was 
calculated from the dose administered to humans.[38] All administrations were done by 
means of an oral gavage, once a day for three days in the period of the most intensive 
inflammation (days 3, 4 and 5 after TNBS administration). 
Assessment of colonic injury and inflammation 
During the 10 days that lasted the assay animals were monitored and clinical activity 
score of colitis was calculated. At day 10 (after TNBS administration) the rats were 
killed with an overdose of anesthesia (dolethal
®
) then the abdomen was opened and the 
distal colon was removed. The samples of inflamed tissue were excised to measure the 
ratios of distal colon weight to body weight (colon/body ratio) and later a histological 
evaluation was carried out. 
Clinical activity score system 
Colitis activity was quantified with a clinical score assessing weight loss, stool 
consistency and rectal bleeding.[39,40] 
Control Range Score 
% Weight loss 
<1% 0 
1-5% 1 
5-10% 2 
10-20% 3 
>20% 4 
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Stool consistency 
Well-formed pellets 0 
Pasty and semi-formed stools 2 
Liquid stools or absence 4 
Bleeding 
No blood 0 
Positive finding 2 
Gross bleeding 4 
The sum of these scores formed the clinical score that ranges from 0 (healthy) to 12 
(maximal activity of colitis). Rats that died or had to be sacrificed before day 10 were 
given a score of 12. 
Determination of colon/body weight ratio 
Once the animals were sacrificed, the abdomen was opened and the distal colon was 
rapidly excised and opened longitudinally along the mesenteric edge. The colon was 
washed with 0.9% (w/v) saline and placed with the mucosal surface upward over a glass 
plate and then weighted.[41] The ratio of the 8 cm segment distal colon weight was 
calculated as an index of colonic tissue edema. 
Myeloperoxidase activity 
The activated neutrophils into the inflamed tissue has peroxidase enzyme substantially 
expressed. For this reason, myeloperoxidase activity can be measured as index of 
inflammation. Myeloperoxidase activity was analyzed according to established method 
with some modification.[42] Colon tissue in presence of 750 µL of HTAB buffer (0.5% 
in 80 mM phosphate buffer pH 5.4) on ice was homogenized and centrifuged (-4ºC, 
10,000 rpm) during 15 min. Supernatant was taken and incubated at 37ºC during 5 min 
with the mixture: 75 µL of phosphate buffer pH 7.4, 10 µL of phosphate buffer pH 5.4 
and 0.026% hydrogen peroxide (10 µL). After that, 20 µL of TMB 18 mM (dissolved in 
8% DMF) were added to the previous mixture and intubated. The reaction was stopped 
after 10 min by the adding of 15 µL of H2SO4 2N. Myeloperoxidase activity was 
determined in the supernatant by spectrophotometric measures at 450 nm. 
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Histological evaluation 
Two tissue samples (3 cm distal and proximal samples) were excised from each colon 
and maintained in paraformaldehyde (4%, v/v) for 24 h and then changed to a 
paraformaldehyde (0.4%, v/v) medium for microscopic studies. These tissue samples 
were processed routinely and embedded in paraffin. Longitudinal sections (5 µm) were 
stained with hematoxylin and eosin. Microscopic assessment by light microscope was 
performed blind on coded slices. 
Statistical analysis 
To compare the clinical activity score and the colon/body weight ratio between groups 
the t-student test was performed using SPSS version 22.0 for Windows (SPSS Inc., 
USA). 
 
RESULTS AND DISCUSSION 
Synthesis of gated magnetic micro-sized mesoporous silica particles 
Magnetic nanoparticles (MNPs) coated with oleic acid were prepared by a co-
precipitation procedure that used a mixture of FeCl3 and FeCl2 and ammonium 
hydroxide.[43] Moreover, mesoporous silica was prepared following the “atrane route” 
with small modifications.[44,45] In this synthetic protocol n-cetyltrimethylammonium 
bromide (CTABr) was used as structural directing agent and tetraethylortosilicate 
(TEOS) as silica source. MNPs were suspended in water and incorporated into the 
synthesis crude before the addition of NaOH. The resulting brownish powder was 
washed and the surfactant was subsequently removed by calcination. This procedure 
yielded the final magnetic mesoporous silica micro-sized inorganic solid (S0). Once the 
magnetic mesoporous support was synthesized, the pores of the siliceous phase were 
loaded with safranin O or hydrocortisone (as a model drug in our study) and the external 
surface functionalized with the bulky azo derivative 1. This synthetic protocol yielded 
micro-sized magnetic solids S1 and S2 (see Scheme 1). It was expected that the bulky 
azo derivative 1 would inhibit the leaching of the cargos from the pores. Moreover, 
cargo delivery was expected to be observed in the presence of sodium dithionite (able to 
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broke azo linkages) or partially at acidic pH (due to partial hydrolysis of the urea moiety 
that linked azo derivative 1 onto the external surface of the inorganic support).  
Scheme 1. Magnetic micrometric silica mesoporous support loaded with safranin O 
(S1) or hydrocortisone (S2) and capped with a bulky azo derivative. Safranin O or 
hydrocortisone were released in the presence of an azoreductor. 
 
 
Scheme 2. Synthetic route for the preparation of 1. 
 
Azo derivative 1 was obtained in a one-step procedure (Scheme 2) reacting Congo red 
(1a) with (3-isocyanatopropyl)triethoxysilane (1b). The final azo derivative containing 
a trilakoxysilane moiety (1) was fully characterized using 
1
H and 
13
C-NMR and HRMS. 
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Figure 1. Powder X-ray patterns at A) high angles and B) low angles of oleate-
stabilized MNPs, magnetic micrometric mesoporous silica particles as-synthesized, S0, 
S1 and S2. 
Characterization of the materials 
All the prepared materials were characterized using powder X-ray diffraction (PXRD), 
transmission electron microscopy (TEM), scanning transmission electron microscopy 
(STEM), N2 adsorption-desorption isotherms and thermogravimetric measurements. 
Figure 1 shows the PXRD patterns (at high and low angles) of oleate-stabilized MNPs, 
the magnetic mesoporous microparticles as-made, S0, S1 and S2. PXRD of oleate-
coated MNPs (see Figure 1) showed the five typical high-angle reflections of magnetite 
phase indexed as (220), (311), (400), (511) and (440) Bragg peaks. The same peaks 
were observed for the as-made microparticles, S0, S1 and S2 materials but with a 
marked decrease in intensity (see again Figure 1). This intensity loss was ascribed to the 
inclusion of MNPs into the inorganic mesoporous matrix. Low angle PXRD pattern of 
as-made microparticles (Figure 1) displayed the typical reflections of a hexagonal-
ordered mesoporous system that can be indexed as (100), (110), (200) and (210) Bragg 
peaks. A shift of the (100) peak in calcined S0 solid was clearly observed. This 
displacement is consistent with an approximate cell contraction of 3.64 Å and is 
attributed to the condensation of silanol groups during the calcination step. The 
presence of the characteristic (100) reflection in the diffraction pattern of S1 and S2 
clearly indicated that the mesoporous structure was preserved throughout the filling 
process with safranin O (S1) or hydrocortisone (S2) and the anchoring of the azo 
derivative 1 onto the external surface of the microparticles. 
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Figure 2. (a) STEM images of S0 microparticles, (b) silica mapping, and (c) iron 
mapping. 
 
TEM images of solid S2 showed the typical porosity associated with MCM-41 
mesoporous silica (see Supporting Information). Besides, MNPs were observed, as 
small dark dots randomly distributed. STEM images of solid S0 (iron mapping) 
indicated that MNPs are uniformly distributed through the mesoporous silica 
microparticles (Figure 2). Moreover, in order to assess the magnetic behavior of S0, 
field dependent magnetization curves measured at 298 K were obtained. The curves 
displayed no hysteresis loops and showed coercivity values near zero, in agreement with 
a typical superparamagnetic behavior at room temperature. The saturation 
magnetization value for S0 was 1.5 emu/g. This magnetization value is close to those 
reported in the literature for other magnetic mesoporous silica particles, which are 
typically in the 1.7-10 emu/g range.[43] 
 
Table 1. BET specific surface area values, pore volumes and pore sizes for S0, S1 and 
S2. 
 SBET 
(m
2
 g
-1
) 
pore 
volume
a
 
(cm
3
 g
-1
) 
pore 
size
a,b
 
(nm) 
S0 1097 0.95 2.66 
S1 552 0.43 - 
S2 355 0.17 - 
a
 Total pore volume according to the BJH model. 
b
 Pore size estimated by using the BJH model applied on the adsorption branch of the 
isotherm, for P/P0 < 0.6, which can be associated to the surfactant generated mesopores. 
 
a) b) c)
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N2 adsorption-desorption studies on S0, S1 and S2 were also carried out (see Supporting 
Information). Solid S0 showed a typical curve for mesoporous silica materials, with an 
adsorption step at intermediate P/P0 values (0.2-0.4). The isotherm was classified as 
type IV in which the absorption step deals with nitrogen condensation inside the 
mesopores. The pore diameter of S0 was calculated using the Barret-Joyner-Halenda 
(BJH) method.[46] The narrow BJH pore distribution observed and the absence of a 
hysteresis loop in the 0.2-0.4 P/P0 interval suggested the existence of uniform 
cylindrical mesopores. Values of pore diameter of 2.66 nm and pore volume of 0.95 cm
3
 
g
–1
, calculated on the adsorption branch of the isotherm, were found. Pore diameter 
estimated from TEM images agree with this value. The application of the Brunauer–
Emmett–Teller (BET) model gave a value of 1097 m2 g–1 for the total specific surface 
area.[47] On the other hand, the N2 adsorption-desorption isotherms of solids S1 and S2 
are typical of mesoporous systems with partially filled mesopores, and a significant 
decrease in both the adsorbed N2 volume and the specific surface was clearly observed 
(Table 1). This reduction in the BET surface, compared with that of S0, was ascribed to 
the loading of pores with safranin O (S1) or hydrocortisone (S2) and the 
functionalization of the external surface with the bulky azo derivative 1 (for both 
solids). 
 
Table 2. Content of total organic matter (in g) per gram of SiO2, content of azo 
derivative (in g) per gram of SiO2 and dye/drug released (in µg) per mg of solid in S1 
and S2. 
 
solid 
organic content 
(g/g SiO2) 
gate 
(g/g SiO2) 
dye/drug 
release 
(µg/mg solid) 
S1 0.19 0.13 2.4 
S2 0.41 0.15 28.1 
 
Total organic matter on solids S1 and S2 was determined by thermogravimetric analysis 
and 
1
H NMR (Table 2). The amount of anchored azo derivative anchored onto S1 and 
S2 was determined by 
1
H NMR upon dissolving the corresponding sample in 
NaOD/D2O in the presence of tetraethyl ammonium bromide as internal standard.[48] 
The organic content in solid S1 was lower than that found in S2. This is consistent with 
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the higher specific surface observed for S1 (see Table 1) and suggests that loading 
hydrocortisone into the pores of the inorganic scaffold was more effective than that for 
safranin O (to obtain S1).  
FT-IR analysis comparing the calcined framework (S0) with the loaded and gated 
material (S2) were carried out to confirm the functionalization of the material (see 
Supporting Information). S0 microparticles presented two main bands at 1062 and 954 
cm
-1
 that corresponds to Si-O-Si stretching vibrations. Both bands were also present in 
the FT-IR spectrum of S2 microparticles. Besides, S2 also showed signals at 2935 and 
2877 cm
-1
 typical of C-H stretching vibrations and attributed to the loaded 
hydrocortisone and the grafted azo derivative 1. Moreover, the typical carbonyl (from 
the urea that linked 1 onto the external surface of the inorganic scaffold) and azo 
stretching vibrations appeared at 1635 and 1562 cm
-1
 in S2 microparticles. 
Cargo release from S1 and S2 
Payload release from solids S1 and S2 at acidic (2.0 and 4.5) and neutral (7.4) pH was 
tested. Besides, the controlled release behavior of both solids at neutral pH (7.4) in the 
absence or presence of the reducing agent sodium dithionite was also studied.[49,50] 
These pH values were selected taking into account the possible use of S2 as vehicle for 
controlled release in colon and inflammatory bowel disease scenarios. At this respect, 
pH 2.0 is typical of gastric juices, pH 4.5 is found in the transition from stomach to 
intestines (this pH can also be found in stomach in fed conditions and in the colon of 
IBD patients), whereas pH 7.4 is typically found in the intestine. On the other hand, 
sodium dithionite mimics the presence of azoreductase enzymes on the colon. Cargo 
release profile for solid S1 and S2 are shown in Figures 3 and 4. 
As could be seen in Figure 3, aqueous suspensions of S1 showed negligible safranin O 
release at neutral pH. However, as a clear contrast, a marked delivery of entrapped 
safranin O was seen in the presence of sodium dithionite, showing a sustained release 
profile that reaches ca. 80% of maximum dye delivered after 4 h. The observed delivery 
is attributed to the sodium dithionite, which is able to reduce azo groups in the capping 
molecule 1 resulting in pore opening and safranin O release. At pH 4.5, S1 showed a 
low dye delivery (ca. 20% of maximum dye released after 8 h). At pH 2.0, safranin O 
delivery reaches 60% of the maximum drug release after 8 h. The observed release at 
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acidic pH is attributed to the hydrolysis of urea group in highly acidic environment. 
Maximum release of safranin O from S1 was 2.4 µg/mg solid at pH 7.4 in the presence 
of a reducing agent. For S2 solid, a nearly “zero” release of hydrocortisone at pH 7.4 
was observed whereas a sustainable delivery of the drug (ca. 75% of maximum 
hydrocortisone release after 6 h) was produced in the presence of sodium dithionite (see 
Figure 4). Again, cargo release was ascribed to the reduction of the azo bond by the 
reducing agent. However, in contrast with the controlled release behavior of S1 in acidic 
environments, a “zero” release of hydrocortisone at pH 4.5 and 2.0 was observed.  
Maximum release of hydrocortisone from S2 was 28.1 µg/mg solid at pH 7.4 in the 
presence of a sodium dithionite. This different behavior is tentatively attributed to the 
lower solubility of hydrocortisone at acidic pH when compared with safranin O. 
 
 
Figure 3. Release kinetics of safranin O from S1 in aqueous solution at pH ≈ 2 (square), 
pH ≈ 4.5 (circle), pH ≈ 7.4 (triangle) and pH ≈ 7.4 in the presence of sodium dithionite 
(2 mg/mL) (cross). 
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Figure 4. Release kinetics of hydrocortisone from S2 in aqueous solution at pH ≈ 2 
(square), pH ≈ 4.5 (circle), pH ≈ 7.4 (triangle) and pH ≈ 7.4 in the presence of sodium 
dithionite (2 mg/mL) (cross). 
In vitro digestion model assay 
Despite the partial payload delivery from S1 at acidic pH shown above, it has to be 
noted that permanence of the particles in the stomach is usually less than 2 h and 
therefore only a partial cargo delivery is expected to occur before targeting colonic 
tissues. In fact, in order to study more in-depth, the possible application of the prepared 
magnetic microparticles as suitable carriers for cargo delivery in colon, payload release 
from S1 was further tested in a model of digestion using simulated solutions. The model 
used was a modification of the introduced by Oomen and co-workers which is a three-
step procedure simulating digestive process in mouth, stomach and small 
intestine.[51,52] Moreover, we introduced a fourth step to simulate the digestive 
process in colon. The results obtained with S1 microparticles are shown in Figure 5. 
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Figure 5. Release kinetics of safranin O from S1 in simulated GIT fluids. 
 
As could be seen in Figure 5, a nearly “zero release” was observed during the first 5 
min in which the solid was in contact with simulated saliva. However, a moderate cargo 
release (0.6 µg/mg of safranin O for S1) was observed in the stomach due to partial pore 
opening (hydrolysis of the urea bond that linked the bulky azo derivative onto the 
microparticle surface) in the acidic environment of this part of the GIT. In conditions 
simulating small intestine, no further delivery of safranin O was observed. Finally, a 
marked cargo release was found in simulated colon conditions (1.8 µg/mg of safranin O 
for S1). This marked delivery observed is clearly related with the presence of sodium 
dithionite, which is able to reduce azo bonds of the capping ensemble in S1 
microparticles.  
In vivo pharmacokinetics studies 
To prove the specific colon delivery and quantify cargo release from the synthesized 
microparticles in plasma and colon, in vivo pharmacokinetic studies were carried out. 
For this purpose, male Wistar rats were divided into three groups (see Experimental 
section). Rats in group 1 were treated with 1 mL of safranin O solution (150 µg/mL 
saline). The subjects from group 2 were treated with 1.75 mL of a suspension of S1 
microparticles (containing 60 mg of solid that releases ca. 150 µg of safranin O). 
Finally, group 3 rats were subjected to the same treatment than those in group 2 but, in 
addition, a magnetic belt in the lower part of the waist was implemented in order to 
increase the retention time of the microparticles in the last segment of the bowel due to 
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the presence of magnetic nanoparticles in S1. Safranin O concentrations in plasma are 
shown in Figure 6. As could be seen, subjects from group 1 (that received the safranin 
O solution) showed high plasma levels of the dye (maximum value was ca. 0.35 µg/mL 
after 30 min). However, rats in group 2 and 3 presented negligible safranin O systemic 
absorption. The marked decrease of safranin O in the plasma of the subjects pertaining 
to groups 2 and 3 indicate a remarkable protection of the cargo in S1 that inhibited 
absorption of the cargo in the intestine.    
 
 
Figure 6. Safranin O concentration (µg/mL) in plasma for subjects of group 1 (safranin 
O solution), group 2 (S1 suspension) and group 3 (S1 suspension + magnetic belt). 
 
Besides, the presence of safranin O in cecum, colon and feces released from the 
particles was also evaluated. As could be seen in Figure 7, subjects in group 1 showed 
negligible safranin O levels in cecum, colon and feces. Moreover, the levels of the dye 
in cecum and feces (for the individuals of groups 2 and 3 treated with S1) were lower 
when compared to levels observed in colon. The remarkable concentration of safranin O 
in colon for subjects from groups treated with S1 (2 and 3) strongly suggested that 
microparticles were opened selectively in the reductive environment of this part of the 
GIT. Besides, safranin O levels in colon of individuals of group 3 are significantly 
higher than those found for rats in group 2. This fact was ascribed to the enhanced 
retention of S1 microparticles in the colon because of the presence of the magnetic belt. 
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Figure 7. Safranin O concentration (µg/mL) released from the particles in cecum, colon 
and feces for subjects of group 1 (safranin O solution), group 2 (S1 suspension) and 
group 3 (S1 suspension + magnetic belt). 
 
The results presented above evidence the specific safranin O delivery into the colon and 
the avoidance of systemic absorption when rats were treated with S1. Moreover, 
improved results (in terms of concentration of dye in colon) were obtained for rats 
wearing a magnetic belt. 
In vivo efficacy studies. Induction of colonic inflammation 
In order to test the in vivo efficacy of the prepared microparticles a model of chronic 
inflammation in colon was used. For this purpose, male Wistar rats were treated with an 
enema containing trinitrobenzene sulfonic acid (TNBS) in ethanol-water 1:1 v/v 
mixture (see Experimental section for details). The main advantages of this model are 
its simplicity, reproducibility and time and dose related development of 
inflammation.[53,54] The development of the inflammation was monitored daily. It was 
observed that rats suffered from diarrhea and weight-loss but not rectal bleeding. 
The efficacy of the magnetic microparticles loaded with hydrocortisone (S2) for the 
treatment of TNBS-induced colitis in rats was assessed. For this purpose, rats were 
divided into five groups (see Experimental section for details). Rats in group 1 were 
treated with 1.5 mL of saline solution (positive control). Group 2 was formed by rats 
treated with a suspension (60 mg in 1.5 mL of saline) of S0 microparticles (as a control 
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to assess the effect of the inorganic magnetic scaffold). Individuals in group 3 received 
a hydrocortisone solution (1.5 mg in 1.5 mL of saline). A suspension of S2 
microparticles (60 mg in 1.5 mL of saline) was administered to rats pertaining to group 
4. Finally, group 5 was constituted by rats treated with a suspension of S2 (60 mg in 1.5 
mL of saline) wearing also a magnetic belt to evaluate if there was any improvement 
when the retention time of microparticles at the end of the GIT was lengthened. The 
efficacy of S2 microparticles was evaluated by comparing the clinical activity score (see 
Experimental section), colon/body ratio (in g/g) and histological damage among the 
different groups. 
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Figure 8. Pictures of rat colon after the induction of colitis with TNBS sacrificed on 
day 10. A) healthy control (no TNBS administered); B) group 1 as positive control 
(treated with saline solution); C) group 2 (treated with S0); D) group 3 (treated with 
hydrocortisone); E) group 4 (treated with a S2 suspension); F) group 5 (treated with S2 
+ magnetic belt). 
 
In a first step, the colon appearance of rats pertaining to groups 1-5 was visually 
assessed (Figure 8). All rats from groups 1 to 5 were killed on day 10. Figure 8A show 
the typical aspect of a healthy colon in rats not treated with TNBS. Figure 8B and 8C 
show opened colons of rats pertaining to groups 1 (treated with saline as positive 
control) and 2 (administered with a suspension of S0 microparticles). Both colons are 
closely similar showing necrotic tissue and presented a thick and rigid bowel. When 
hydrocortisone was administered (rats of group 3, see Figure 8D) some tissues started to 
heal, necrotic zones and thickened tissues decreased to some extent but they were still 
largely present. As clear contrast, colon of rats treated with S2 microparticles (Figure 
8E) showed middle to mild injuries with the presence of necrotic areas but with tissues 
no longer thickened. Finally, Figure 8F showed the open colon of a rat pertaining to 
group 5 (treatment with S2 microparticles and the rats wearing a magnetic belt). As 
could be seen, the aspect of the colon resembles that of healthy individuals (see Figure 
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8A) presenting small injuries. The observed results pointed to a selective release of the 
entrapped hydrocortisone in S2 microparticles in the colon of TNBS-treated rats. 
Besides, the efficacy of the treatment of S2 coupled to a magnetic field was higher than 
that found with the microparticles alone. This fact was ascribed to the enhanced 
retention time of S2 microparticles in colon that resulted in a more effective delivery of 
hydrocortisone in the injured tissues. In fact, after the treatment, rats from group 4 and 5 
started to gain weight and have normal stool. Besides, some of the rats from group 3 
(receiving hydrocortisone solution) gained weight and improved their health condition 
as well. On the contrary, rats treated with saline solution or S0 (groups 1 and 2) 
continued losing weight and had diarrhea during all the experiment time. 
In a second step, the effects of different formulations on the colon/body ratio and 
clinical activity score were assessed (see Experimental section). The obtained results are 
shown in Figures 9 and 10. As could be seen in Figure 9, the colon/body ratio in TNBS-
treated rats administered with saline (positive control) was in the 0.30-0.33 g/g interval. 
Nearly the same interval was observed for rats in group 2 (treated with S0 
microparticles). However, as a clear contrast, a marked reduction in the colon/body ratio 
for rats in groups 4 and 5 was observed (ca. 0.04-0.19 g/g for individuals treated with 
S2 and wearing a magnetic belt). These reductions in the colon/body ratio indicated that 
S2 microparticles reached the site of action and released hydrocortisone more 
efficiently. These results contrast with those obtained in group 3 (rats treated with 
hydrocortisone administered orally as a solution) that presented high variability with 
cases of real improvements mixed with individuals in which no effect was observed. 
This was reflected in a large colon/body ratio range (0.05-0.30 g/g) and suggested that 
hydrocortisone is probably adsorbed before the drug reaches the site of action.  
Almost the same results were obtained with the clinical activity score (see Figure 10). 
Colitis activity was quantified with a clinical score assessing weight loss, stool 
consistency and rectal bleeding. The sum formed the clinical score that ranges from 0 
(healthy) to 12 (maximal activity of colitis).[39,40] Rats that died or had to be sacrificed 
before day 10 were given a score of 12. As could be seen in Figure 10, rats in group 1 
(treated only with saline) presented a clinical score in the 7-9.5 range indicative of 
marked colitis activity. Besides, a marked reduction of the clinical activity score was 
observed in the groups treated with S2 microparticles (4 and 5) indicative of a proper 
delivery of hydrocortisone in the injured colonic tissue.   
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Moreover, myeloperoxidase measurements agree with the clinical activity score 
obtained. These measurements indicated a myeloperoxidase activity decrease of 47% 
after administration of free hydrocortisone. However, after oral administration of S2 
microparticles in rats, a marked 94% decrease in myeloperoxidase activity was 
observed. This reduction in enzyme activity clearly indicated that inflammation was 
reduced with the S2 administration. 
 
 
Figure 9. Colon/body weight ratio of animals with TNBS-induced colitis after 
treatment with saline solution (group 1, positive control), S0 (group 2), hydrocortisone 
(group 3), S2 (group 4) and S2 + magnetic belt (group 5). In each box is represented the 
median value, 25% and 75% percentils, minimal and maximal values (
a 
statistical 
significant difference (P < 0.05) compared to saline). 
 
 
Figure 10. Clinical activity score of animals with TNBS-induced colitis after treatment 
with saline solution (group 1, positive control), S0 (group 2), hydrocortisone (group 3) 
S2 (group 4) and S2 + magnetic belt (group 5). In each box is represented the median 
value, 25% and 75% percentils, minimal and maximal values (
a,b 
statistical significant 
difference (P < 0.05) compared to saline and empty MCM, respectively). 
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Histological evaluation 
Finally, a histological examination of colon tissues of a healthy rat (control without 
TNBS administration), and of individuals treated with saline (group 1), S0 (group 2), 
hydrocortisone (group 3), S2 (group 4) and S2 + magnetic belt (group 5) was carried 
out. All samples were taken from rats sacrificed on the 10
th
 day after administration of 
TNBS (see Experimental section for details). The obtained results are shown in Figure 
11. Rats without TNBS treatment showed a normal colon structure with healthy 
mucosa, enterocytes and goblet cells and between them connective tissue (lamina 
propria), muscularis mucosae and normal submucosa and muscularis externa (see 
Figure 11A). Tissues of individuals of groups 1 and 2 showed loss of the necrotic 
mucosa and substitution with granulation tissue. A strong inflammatory process was 
present in the lamina propria, submucosa and muscularis externa (Figures 11B and 
11C). As can be seen in Figure 11B and 11C, process of ulceration with fibrinoid 
necrosis of the mucosal surface and granulation tissue below the necrotic tissue were 
observed. Animals in group 3 presented superficial erosion, thinning of the mucosa 
accompanied by thickening of the muscularis mucosae, and a chronic inflammatory 
process that affects the mucosa and submucosa with early development of lymphoid 
follicles (see Figure 11D). Besides, few parts with normal mucosa structure but 
presence of strong follicular hyperplasia in the muscularis externa and parts with 
necrosis, loss of mucosa and substitution with granulation tissue and inflammation 
process were also observed (see again Figure 11D). On the other hand, animals that 
received S2 microparticles treatment (groups 4 and 5) showed substantially normal 
mucosal structure with slight presence of chronic inflammation in the muscularis 
propria (see Figure 11E and 11F). 
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Figure 11. Histology of a representative colon specimen of A) healthy rat; B) group 1 
as positive control (treated with saline solution); C) group 2 (treated with S0); D) group 
3 (rats administered with hydrocortisone); E) group 4 (subjects treated with a S2 
suspension); F) group 5 (treated with S2 + magnetic belt). m: muscularis mucosae, s: 
submucosa, in: infiltration, R: regenerated crypts and mucosal architecture,  absence 
of surface epithelium. 
 
The results of the histological studies showed that tissues of saline treated TNBS 
individuals (group 1) presented strong inflammation accompanied with necrosis and 
loss of the mucosa. Similar results were obtained for tissues isolated from individuals of 
group 2 (treated with suspensions of S0 microparticles). As marked contrast, tissues 
from rats in groups 4 and 5 (treated with S2 and S2 + magnetic belt respectively) 
showed a decrease in inflammation followed by intensive regeneration and almost 
normal mucosal structure.  
Histological evaluation provided additional information to that obtained by the clinical 
activity score and colon/body weight ratio observations, thus confirming the usefulness 
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of the S2 microparticles in the treatment of IBD. S2 were even more effective if a 
magnetic field was applied to retain particles in the damaged intestinal areas. The 
results obtained with S2 microparticles showed enhanced efficacy with respect of other 
formulations [42,55] with the added benefit of having no systemic intervention. 
 
CONCLUSIONS 
A new oral colon drug delivery device was designed, prepared and its efficacy in the 
treatment of IBD was evaluated in vivo in a TNBS colitis induced rat model. The 
nanodevices consisted on magnetic mesoporous silica microparticles loaded with 
safranin O (S1) or with hydrocortisone (S2) and functionalized in the external surface 
with a bulky azo derivative covalently grafted through urea bonds. Both materials 
remained capped at neutral pH whereas a marked payload release was observed in the 
presence of a reducing agent (such as sodium dithionite). This cargo delivery was 
ascribed to the reduction of azo bonds in the capping ensemble. Besides, a certain 
safranin O release was observed at acidic pH mainly related with the partial hydrolysis 
of the urea bonds that linked the azo derivatives onto the external surface of the loaded 
scaffold. In vivo pharmacokinetic studies carried out with S1, evidenced specific 
safranin O delivery in colon and the absence of safranin O systemic absorption 
(negligible concentrations of safranin O in plasma). Moreover, improved results (in 
terms of concentration of dye in colon) were obtained for rats wearing a magnetic belt. 
Colon/body weight ratio, clinical activity score systems and histology evaluation 
showed that rats with a model of chronic inflammation in colon and treated with S2 
microparticles had an improvement in the pathology, being more effective when a 
magnetic field was externally applied to lengthen the retention time in the areas of 
interest. S2 and specially S2 + magnetic belt improved efficacy of hydrocortisone in the 
in vivo induced colitis model. In conclusion, we demonstrated that our system can be 
used to specifically deliver drugs or other agents in the last part of intestine while 
decreasing the systemic absorption; both effects contribute to increase efficacy for the 
treatment of inflammatory bowel disease and to reduce adverse effects of drugs.  
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